Deutsche Bank Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $270
Deutsche Bank Adjusts IQVIA Holdings Price Target to $270 From $275, Maintains Buy Rating
Barclays Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $260
Barclays Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $260
Redburn Atlantic Initiates Coverage On IQVIA Hldgs With Buy Rating, Announces Price Target of $276
Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $286
IQVIA Holdings Is Maintained at Outperform by Evercore ISI Group
IQVIA Hldgs Analyst Ratings
Evercore Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $265
Evercore ISI Adjusts Price Target on IQVIA Holdings to $265 From $270, Maintains Outperform
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Acumen Pharmaceuticals (ABOS)
Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating
Truist Financial Gives a Buy Rating to IQVIA Holdings (IQV)
IQVIA Holdings Is Maintained at Neutral by Baird
IQVIA Hldgs Analyst Ratings
Baird Maintains IQVIA Holdings(IQV.US) With Hold Rating, Raises Target Price to $256
Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and BioMarin Pharmaceutical (BMRN)
IQVIA Hldgs Analyst Ratings
RBC Initiates IQVIA Holdings at Outperform With $275 Price Target